Department of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People's Republic of China.
Hematology. 2021 Dec;26(1):1040-1045. doi: 10.1080/16078454.2021.2009642.
Our objective is to retrospectively analyze the response to low dose of homoharringtonine (HHT) and cytarabine-based priming induction regimens in patients above 70 years with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
We retrospectively analyzed these very elderly newly diagnosed patients with AML and high-risk MDS, who received low dose of HHT and cytarabine-based priming induction regimens between March 2006 and September 2019.
Of the 24 patients, 11 patients (47.8%) achieved complete remission (CR) and 3 (13%) partial remission, and the overall response rate was 60.9%. The estimated median overall survival (OS) time was 12 months and the 1-year OS rate was 47.8%. Patients without CR and Charlson's Comorbidity Index > 2 may be the two independent prognostic factors. The median OS was significantly higher for patients with CR after induction chemotherapy than those without CR (22.93 . 8.5 months, < .01).
Our study provides a hint of the efficacy of low dose of HHT and cytarabine-based priming induction regimens for patients aged over 70 years with AML and high-risk MDS should be further studied.
我们的目的是回顾性分析低剂量高三尖杉酯碱（HHT）和阿糖胞苷为基础的预激诱导方案在 70 岁以上急性髓系白血病（AML）和高危骨髓增生异常综合征（MDS）患者中的疗效。
我们回顾性分析了 2006 年 3 月至 2019 年 9 月期间接受低剂量 HHT 和阿糖胞苷为基础的预激诱导方案的这些非常高龄的新发 AML 和高危 MDS 患者。
24 例患者中，11 例（47.8%）达到完全缓解（CR），3 例（13%）部分缓解，总缓解率为 60.9%。估计的中位总生存期（OS）时间为 12 个月，1 年 OS 率为 47.8%。未达到 CR 和 Charlson 合并症指数>2 可能是两个独立的预后因素。诱导化疗后达到 CR 的患者的中位 OS 明显高于未达到 CR 的患者（22.93±8.5 个月，<0.01）。
我们的研究提示低剂量 HHT 和阿糖胞苷为基础的预激诱导方案对于 70 岁以上 AML 和高危 MDS 患者可能有效，应进一步研究。
